In May 2025, the Company reported additional long-term data from its nonhuman primate (“NHP”) study that demonstrated durable and consistent FVIII activity levels through approximately 19 months. Mean ...

Debt Facility In connection with the New JV, Ganfeng has agreed to provide Lithium Argentina with a $130 million, six-year debt facility bearing interest at SOFR plus 2.5%. The Debt Facility enhances ...

Brex reports that a business credit card can help separate finances, build credit, and offer rewards, but requires ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four ...

Lithium Argentina AG. ("Lithium Argentina" or the "Company") (TSX: LAR) (NYSE: LAR) is pleased to announce the execution of a framework agreement (the ...

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) ...

DURHAM, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

TLGY Acquisition Corp. Announces Business Combination and Approximately $360 Million PIPE Financing to Form StablecoinX, an Ethena Stablecoin-Focused Treasury Company ...

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients</p ...

RICHMOND, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2025 financial ...

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia ...